Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy addresses from a comprehensive and multidisciplinary approach the translational aspects and clinical perspectives of nano-pharmacokinetics using cancer as a model disease. Nano-pharmacokinetics is emerging as an important sub discipline of nanoscience and medical sciences because of the increasing safety issues of nanosystems on living organisms. This book reports the dynamics of nanosystems in living organisms for better understanding of nanotoxicity, pharmacology, biochemistry, physiology and medicine perspectives. It further examines current progress of state-of-the art pharmacokinetics mechanisms, which will be of great help to develop more clinical-oriented nanosystems with a wide safety margin. The book is divided into three sections: the first section focuses on the concept of pharmacokinetics with state-of-the-art Nano-Pharmacokinetics (NPK). The second section looks at the engineering of nanoparticles and pharmacokinetics clinical development. The final section focuses on Nano-Pharmacokinetics and Theranostics, elaborating the basic question of how pharmacokinetics of nanomaterials relate to their end applications such as cancer therapy. Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy will be useful to researchers in the field of nanoparticle based targeted drug delivery including pharmaceutical scientists, material scientists, chemists, nanotechnologists, biomedical scientists, and clinicians.
1. Nano-Pharmacokinetics and Theranostics - p. Page i 2. Cover - p. Page i 3. Title page - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iii 6. Contents - p. Page vi 7. List of contributors - p. Page vii 8. About the editors - p. Page vii 9. Preface - p. Page ix 10. Acknowledgment - p. Page xi 11. List of Illustrations - p. Page xiii 12. List of Tables - p. Page xiv 13. Chapter 1 : Nanomaterials and pharmacokinetics - p. Page xiv 14. Chapter 2 : Nanopharmacokinetics: routes of administration and predictive models for nanopharmacokinetics - p. Page 13 15. Chapter 3 : Nano-pharmacokinetics: interface of physics, chemistry and biology - p. Page 28 16. Chapter 4 : Nanomaterials exposure to human - p. Page 48 17. Chapter 5 : Engineered nanomaterials and pharmacokinetics - p. Page 68 18. Chapter 6 : Regulatory, safety, and toxicological concerns of nanomaterials with their manufacturing issues - p. Page 88 19. Chapter 7 : Nano-pharmacokinetics: biodistribution and toxicology - p. Page 111 20. Chapter 8 : Biological systems and nanopharmacokinetics - p. Page 145 21. Chapter 9 : Nanopharmacokinetics assessment - p. Page 167 22. Chapter 10 : Clinical protocols for nanopharmacokinetics assessment - p. Page 189 23. Chapter 11 : Nano-pharmacokinetics and cancer theranostics - p. Page 216 24. Chapter 12 : Nanopharmacokinetics: key role in in vivo imaging - p. Page 230 25. Chapter 13 : Pharmacokinetics/pharmacodynamics and clinical relationship - p. Page 250 26. Chapter 14 : Nano-pharmacokinetics preclinical to clinical translation - p. Page 267 27. Chapter 15 : Nano-pharmacokinetics: industrial transformation future outlook and conclusion - p. Page 287 28. Index - p. Page 299
Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy addresses from a comprehensive and multidisciplinary approach the translational aspects and clinical perspectives of nano-pharmacokinetics using cancer as a model disease. Nano-pharmacokinetics is emerging as an important sub discipline of nanoscience and medical sciences because of the increasing safety issues of nanosystems on living organisms. This book reports the dynamics of nanosystems in living organisms for better understanding of nanotoxicity, pharmacology, biochemistry, physiology and medicine perspectives. It further examines current progress of state-of-the art pharmacokinetics mechanisms, which will be of great help to develop more clinical-oriented nanosystems with a wide safety margin. The book is divided into three sections: the first section focuses on the concept of pharmacokinetics with state-of-the-art Nano-Pharmacokinetics (NPK). The second section looks at the engineering of nanoparticles and pharmacokinetics clinical development. The final section focuses on Nano-Pharmacokinetics and Theranostics, elaborating the basic question of how pharmacokinetics of nanomaterials relate to their end applications such as cancer therapy. Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy will be useful to researchers in the field of nanoparticle based targeted drug delivery including pharmaceutical scientists, material scientists, chemists, nanotechnologists, biomedical scientists, and clinicians.
1. Nano-Pharmacokinetics and Theranostics - p. Page i 2. Cover - p. Page i 3. Title page - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iii 6. Contents - p. Page vi 7. List of contributors - p. Page vii 8. About the editors - p. Page vii 9. Preface - p. Page ix 10. Acknowledgment - p. Page xi 11. List of Illustrations - p. Page xiii 12. List of Tables - p. Page xiv 13. Chapter 1 : Nanomaterials and pharmacokinetics - p. Page xiv 14. Chapter 2 : Nanopharmacokinetics: routes of administration and predictive models for nanopharmacokinetics - p. Page 13 15. Chapter 3 : Nano-pharmacokinetics: interface of physics, chemistry and biology - p. Page 28 16. Chapter 4 : Nanomaterials exposure to human - p. Page 48 17. Chapter 5 : Engineered nanomaterials and pharmacokinetics - p. Page 68 18. Chapter 6 : Regulatory, safety, and toxicological concerns of nanomaterials with their manufacturing issues - p. Page 88 19. Chapter 7 : Nano-pharmacokinetics: biodistribution and toxicology - p. Page 111 20. Chapter 8 : Biological systems and nanopharmacokinetics - p. Page 145 21. Chapter 9 : Nanopharmacokinetics assessment - p. Page 167 22. Chapter 10 : Clinical protocols for nanopharmacokinetics assessment - p. Page 189 23. Chapter 11 : Nano-pharmacokinetics and cancer theranostics - p. Page 216 24. Chapter 12 : Nanopharmacokinetics: key role in in vivo imaging - p. Page 230 25. Chapter 13 : Pharmacokinetics/pharmacodynamics and clinical relationship - p. Page 250 26. Chapter 14 : Nano-pharmacokinetics preclinical to clinical translation - p. Page 267 27. Chapter 15 : Nano-pharmacokinetics: industrial transformation future outlook and conclusion - p. Page 287 28. Index - p. Page 299
